infectious disease targets
TRANSCRIPT
GeneTAG has four patents awarded and three patents pending for seven novel probe systems that can identify gene mutations and gene signatures that are indicative of infectious diseases, drug-resistant subspecies, and mutation driven cancers.
GeneTAG Technology, Inc.
Error-checking DNA Detection Switch probes
Conventional dual-labeled qPCR probes lack error-checking mechanisms and cannot
provide multi-temperature single base discrimination. GeneTAG Technology has
developed 3 error-checking DNA Detection Switch (DDS) probe systems for high-
fidelity detection and/or amplification. DDS probes employ the interaction of 2
labeled polynucleotide components: a fluorescent probe and a quenching antiprobe.
Probes bind preferentially to their intended targets, turning on signaling, while
dissociating from a nearly complementary antiprobe that otherwise turns off
signaling. This general signaling mechanism is termed a ′DNA detection switch′.
DDS probes are designed to match the target sequence, and antiprobes
are complementary to the probe except for a carefully engineered mismatch. The
thermodynamics of this design facilitates exacting target detection because
the competitive antiprobes bind and quench free-floating probes, preventing the
detection of closely related off-targets. Principles and applications of each error-
checking DDS probe system are described below.
Principles of error-checking DDS probes
Internal DNA Detection Switch probes deliver unparalleled specificity
Flip probes can provide quantitative endpoint detection without a qPCR instrument
ZIPR primer-probes for error-checking qPCR amplification
internal DNA Detection Switch probes: high-specificity, error-checking mechanism
About US
Our mission is to provide superior molecular
detection systems that are precise, simple and
inexpensive.
GeneTAG has four patents awarded and three
patents pending for seven
novel probe systems that can identify gene
mutations and gene signatures that are indicative
of infectious diseases, drug-resistant subspecies,
and mutation driven cancers.
1. Murray JL, Hu P, Shafer DA. Seven novel probe
systems for real-time PCR provide absolute single
base discrimination, higher signaling, and generic
components. (2014). J Mol Diagn. 16, 627–638.
2. Storts DR. Alternative Probe-Based Detection
Systems in Quantitative PCR. (2014). J Mol Diagn.
16, 612-614.
OUR MISSION PUBLICATIONS
Contact Us
GeneTAG Technology, Inc.
3781 Presidential Parkway, Suite 9
Atlanta, GA 30340
Phone: 678-805-8840
E-mail: [email protected]
Website: www.genetagtech.com